AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15530681 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 39
Study 15530681 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza and pneumococcal vaccine
Number of subjects: 39
Study 11586492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day, n = 14)
Number of subjects: 28
Study 11586492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 28
Study 9451630 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (REx)
Number of subjects: 16
Study 9451630 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NoEx)
Number of subjects: 16
Study 8572850 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide IR 2.5 mg
Number of subjects: 285
Study 8572850 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 285
Study 8572850 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 2.0 mg
Number of subjects: 285
Study 8572850 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 2.5 mg
Number of subjects: 285
Study 8572850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 2500368 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermanent vascular access catheters (VACs) maintained without occlusive dressings, antibiotics, repeated flushings or heparin.
Number of subjects: 26
Study 2500368 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermanent vascular access catheters (VACs)
Number of subjects: 26
Study 966146 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered methotrimeprazine
Number of subjects: 13
Study 31218230 — intervention group
Group type: EXPERIMENTAL
Intervention: GET.ON Mood Enhancer Diabetes (GET.ON M.E.D.)
Number of subjects: 40
Study 31218230 — intervention group
Group type: COMPARATOR
Intervention: Online psychoeducation control group
Number of subjects: 40
Study 28017546 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% prilocaine (Xylonaest) in combination with epinephrine 1:100,000
Number of subjects: 31
Study 28017546 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (10 mg Naropin, 5 ml sodium chloride, 1 ml epinephrine)
Number of subjects: 31
Study 26016467 — intervention group
Group type: EXPERIMENTAL
Intervention: Perospirone
Number of subjects: 100
Study 26016467 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 100
Study 23295794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab (15 mg/kg once every 90 days)
Number of subjects: 655
Study 23295794 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy (temozolomide or dacarbazine)
Number of subjects: 655
Study 23295794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Number of subjects: 655
Study 23295794 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy
Number of subjects: 655
Study 21332467 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 1582
Study 21332467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1582
Study 19762088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.2mg/kg every 6h) with nebulized L-epinephrine (0.5mg/kg every 4h)
Number of subjects: 64
Study 19762088 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (0.2mg/kg every 6h) without nebulized L-epinephrine
Number of subjects: 64
Study 19762088 — intervention group
Group type: COMPARATOR
Intervention: Control groups received nebulized or intravenous isotonic saline solution, or both
Number of subjects: 64
Study 16913269 — intervention group
Group type: EXPERIMENTAL
Intervention: H1-antihistamine (loratadine) + intranasal glucocorticosteroid (mometasone furoate)
Number of subjects: 24
Study 16913269 — intervention group
Group type: COMPARATOR
Intervention: Intranasal glucocorticosteroid (mometasone furoate) alone
Number of subjects: 24
Study 15605620 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract STW 3-VI 900 mg once daily
Number of subjects: 140
Study 15605620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 11771826 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 infusion
Number of subjects: 20
Study 11771826 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 and GIK infusion after 10 hours
Number of subjects: 20
Study 11771826 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusates)
Number of subjects: 20
Study 9027913 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 126
Study 9027913 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimalarial chemoprophylaxis in primigravidae
Number of subjects: 126
Study 9027913 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced protein/energy supplementation
Number of subjects: 126
Study 9027913 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation during gestation
Number of subjects: 126
Study 9027913 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation during gestation
Number of subjects: 126
Study 9027913 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation during gestation
Number of subjects: 126
Study 8098059 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere 6-hour infusion at a maximally tolerated dose of 100 mg/m2
Number of subjects: 58
Study 8098059 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxotere 2-hour infusion at a maximally tolerated dose of 115 mg/m2
Number of subjects: 58
Study 3419825 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheedy Disparometer
Number of subjects: 22
Study 3419825 — intervention group
Group type: COMPARATOR
Intervention: Mallett test
Number of subjects: 22
Study 30544179 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirited Life wellness intervention including a 10-week online weight-loss program and monthly health coaching for 24 months
Number of subjects: 719
Study 30544179 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirited Life wellness intervention
Number of subjects: 719
Study 30624670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 12,000 IU
Number of subjects: 379
Study 30624670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 24,000 IU
Number of subjects: 379
Study 30624670 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 48,000 IU
Number of subjects: 379
Study 30624670 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 379
Study 25384514 — intervention group
Group type: EXPERIMENTAL
Intervention: High repetition/low load resistance training (HR/LL‐RT) program, 3 sets of 20 repetitions, two times a week, initial load at 30% of 1-RM for 8 weeks.
Number of subjects: 20
Study 25384514 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 20
Study 22992330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive computerized auditory training
Number of subjects: 48
Study 22992330 — intervention group
Group type: EXPERIMENTAL
Intervention: Set-based analysis of 42 SNPs in the COMT gene
Number of subjects: 48
Study 21706145 — intervention group
Group type: EXPERIMENTAL
Intervention: romiplostim (3 μg/kg weekly for 12 weeks)
Number of subjects: 34
Study 21706145 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study 21706145 — intervention group
Group type: EXPERIMENTAL
Intervention: romiplostim
Number of subjects: 34
Study 17453342 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment for 5 years
Number of subjects: 357
Study 17453342 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen treatment for 2 years
Number of subjects: 357
Study 17453342 — intervention group
Group type: EXPERIMENTAL
Intervention: High HOXB13:IL17BR ratio
Number of subjects: 357
Study 17453342 — intervention group
Group type: EXPERIMENTAL
Intervention: High HOXB13 expression
Number of subjects: 357
Study 17453342 — intervention group
Group type: EXPERIMENTAL
Intervention: IL17BR in systemically untreated cohort
Number of subjects: 357
Study 21615813 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent coronary revascularization (CR) [<2 years]
Number of subjects: 720
Study 21615813 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrecent coronary revascularization (CR) [≥2 years]
Number of subjects: 720
Study 21615813 — intervention group
Group type: EXPERIMENTAL
Intervention: No coronary revascularization (CR)
Number of subjects: 720
Study 21615813 — intervention group
Group type: EXPERIMENTAL
Intervention: Time from CR as a continuous measure
Number of subjects: 720
Study 16272186 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 75mg
Number of subjects: 18
Study 16272186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 16272186 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate 20mg
Number of subjects: 18
Study 11823690 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU), 600 mg/m2 (arm I)
Number of subjects: 192
Study 11823690 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 500 mg/m2 intravenous bolus and interferon-alpha, 5 MU subcutaneously, three times a week (arm II)
Number of subjects: 192
Study 11823690 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin 200 mg/m2 in 2-hour infusion and 5-FU 500 mg/m2 intravenous bolus (arm III)
Number of subjects: 192
Study 9696232 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed immunobeads screen
Number of subjects: 9
Study 9696232 — intervention group
Group type: COMPARATOR
Intervention: SpermMar
Number of subjects: 9
Study 9696232 — intervention group
Group type: COMPARATOR
Intervention: Immunobead test
Number of subjects: 9
Study 8556745 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified toothpaste technique (instructions on spreading paste, limiting expectoration, filtering foam, no rinsing, no eating/drinking for 2 hours)
Number of subjects: 369
Study 8556745 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific instructions on toothpaste use or rinsing)
Number of subjects: 369
Study 2707464 — intervention group
Group type: EXPERIMENTAL
Intervention: Human follicular fluid (FF)
Number of subjects: 31
Study 2707464 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated human follicular fluid (FF)
Number of subjects: 31
Study 2707464 — intervention group
Group type: COMPARATOR
Intervention: Ham's F‐10 medium (control)
Number of subjects: 31
Study 588393 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 20
Study 588393 — intervention group
Group type: COMPARATOR
Intervention: Diethyl ether
Number of subjects: 20
Study 171161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric fat administration (soya bean triglyceride-egg yolk phospholipid emulsion, Intralipid)
Number of subjects: 0
Study 171161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fat administration (soya bean triglyceride-egg yolk phospholipid emulsion, Intralipid)
Number of subjects: 0
Study 30887723 — intervention group
Group type: EXPERIMENTAL
Intervention: Caveolin-1 slow-release material
Number of subjects: 72
Study 29549378 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Dichotic Digits Test and Dichotic Words Test
Number of subjects: 782
Study 29549378 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Evaluation of Language Fundamentals (CELF)
Number of subjects: 782
Study 29549378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic listening tests
Number of subjects: 782
Study 29549378 — intervention group
Group type: EXPERIMENTAL
Intervention: CELF
Number of subjects: 782
Study 27350217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 15
Study 27350217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 25197737 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based oral health education (snakes and ladders game combined with flash cards)
Number of subjects: 120
Study 25197737 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral health education (flash cards once daily for 7 days)
Number of subjects: 120
Study 22676409 — intervention group
Group type: COMPARATOR
Intervention: Education intervention consisting of a 45-minute session on effective telephone referrals, including discussion, video critique, ISBAR practice, and provision of a memory aid.
Number of subjects: 160
Study 22676409 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 160
Study 22676409 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-intervention recordings)
Number of subjects: 160
Study 21436928 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective pharmacy course in anticoagulation management
Number of subjects: 0
Study 21436928 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Living with anticoagulation' assignment
Number of subjects: 0
Study 17189793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nepafenac ophthalmic suspension 0.1%
Number of subjects: 476
Study 17189793 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 476
Study 15343260 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic Fluid Index (AFI)
Number of subjects: 1080
Study 15343260 — intervention group
Group type: COMPARATOR
Intervention: Single Deepest Pocket (2 x 1 pocket)
Number of subjects: 1080
Study 15343260 — intervention group
Group type: EXPERIMENTAL
Intervention: AFI
Number of subjects: 1080
Study 15343260 — intervention group
Group type: COMPARATOR
Intervention: 2 x 1 pocket
Number of subjects: 1080
Study 11585118 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap surgery plus EMD
Number of subjects: 16
Study 11585118 — intervention group
Group type: COMPARATOR
Intervention: Flap surgery plus placebo
Number of subjects: 16
Study 9615303 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy for 12 months
Number of subjects: 18
Study 9615303 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 8074426 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg/day)
Number of subjects: 80
Study 8074426 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol (200 mg/day)
Number of subjects: 80
Study 2684023 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 500 mg daily for 6 weeks
Number of subjects: 50
Study 2684023 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin 500 mg daily for 6 weeks
Number of subjects: 50
Study 2684023 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 50
Study 2684023 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 50
Study 1097740 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oral medrogestone twice daily
Number of subjects: 19
Study 1097740 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg oral medrogestone twice daily
Number of subjects: 19
Study 1097740 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 19
Study 29789445 — intervention group
Group type: EXPERIMENTAL
Intervention: KMC with woolen cap (CAP group)
Number of subjects: 300
Study 29789445 — intervention group
Group type: COMPARATOR
Intervention: KMC without woolen cap (NOCAP group)
Number of subjects: 300
Study 28939427 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of bacterial endotoxin lipopolysaccharide (LPS) at a dose of 2ng/kg body weight
Number of subjects: 22
Study 28939427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 28939427 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of bacterial endotoxin lipopolysaccharide (LPS)
Number of subjects: 22
Study 26643919 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortaleça sua Saúde program (intervention)
Number of subjects: 1085
Study 26643919 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1085
Study 23634717 — intervention group
Group type: EXPERIMENTAL
Intervention: Purse-string suture (PSS)
Number of subjects: 84
Study 23634717 — intervention group
Group type: COMPARATOR
Intervention: Direct suture (DS)
Number of subjects: 84
Study 23634717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 84
Study 21415778 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib 250 mg daily alone (G)
Number of subjects: 115
Study 21415778 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus daily oral UFT (GU)
Number of subjects: 115
Study 21415778 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib plus UFT
Number of subjects: 115
Study 18316792 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (DOC) 75 mg/m² IV every 14 days for four cycles followed by doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC) IV every 14 days for four cycles
Number of subjects: 56
Study 18316792 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m² and cyclophosphamide 600 mg/m² (AC) IV every 14 days for four cycles followed by Docetaxel (DOC) 75 mg/m² IV every 14 days for four cycles
Number of subjects: 56
Study 17159108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D 4,000 IU/day (adults)
Number of subjects: 150
Study 17159108 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin D 400 IU/day (adults)
Number of subjects: 150
Study 17159108 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin D 2,000 IU/day (children/adolescents)
Number of subjects: 150
Study 17159108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D 2,000 IU/day (children/adolescents)
Number of subjects: 150
Study 15251831 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐chiro‐inositol 600 mg orally once daily for 6 to 8 weeks
Number of subjects: 20
Study 10613558 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic saphenous vein harvesting (MIVH)
Number of subjects: 103
Study 10613558 — intervention group
Group type: COMPARATOR
Intervention: Conventional open technique
Number of subjects: 103
Study 7736741 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 20
Study 7736741 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 20
Study 2292637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 64
Study 2292637 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy only (NoCT)
Number of subjects: 64
Study 7375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Björk-Shiley (B-S) valve
Number of subjects: 300
Study 7375893 — intervention group
Group type: COMPARATOR
Intervention: Lillehei-Kaster (L-K) valve
Number of subjects: 300
Study 7375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 7375893 — intervention group
Group type: EXPERIMENTAL
Intervention: Further 9 patients
Number of subjects: 300
Study 30888253 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (50 mg)
Number of subjects: 146
Study 30888253 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (200 µg)
Number of subjects: 146
Study 30888253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 30265431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary hypothermia (saline at 4°C)
Number of subjects: 60
Study 30265431 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypothermia)
Number of subjects: 60
Study 27148802 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRCs (40-million, n=28; 80-million, n=3)
Number of subjects: 31
Study 27148802 — intervention group
Group type: EXPERIMENTAL
Intervention: ADRCs
Number of subjects: 31
Study 27148802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 26276138 — intervention group
Group type: EXPERIMENTAL
Intervention: Government Midwifery Incentive Scheme (GMIS)
Number of subjects: 180
Study 26276138 — intervention group
Group type: EXPERIMENTAL
Intervention: Other interventions to improve access to essential maternal health services
Number of subjects: 180
Study 26276138 — intervention group
Group type: COMPARATOR
Intervention: Traditional birth attendants
Number of subjects: 180
Study 23855503 — intervention group
Group type: EXPERIMENTAL
Intervention: AFXL-PDT
Number of subjects: 10
Study 23855503 — intervention group
Group type: COMPARATOR
Intervention: AFXL
Number of subjects: 10
Study 23855503 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment
Number of subjects: 10
Study 21767584 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 13
Study 21767584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 18309606 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical and thermal cycling (20,000 cycles under 10 N load, immersion in distilled water at 37 degrees C, and thermocycled 3,000 cycles between 5-55 degrees C)
Number of subjects: 84
Study 18309606 — intervention group
Group type: COMPARATOR
Intervention: Control group (specimens tested without aging, only water storage at 37 degrees C for 24 hours)
Number of subjects: 84
Study 16580448 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless bioprostheses (Medtronic Freestyle)
Number of subjects: 24
Study 16580448 — intervention group
Group type: COMPARATOR
Intervention: Stented bioprostheses (Medtronic Mosaic)
Number of subjects: 24
Study 16580448 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 14641691 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micro g nasal 17beta‐estradiol
Number of subjects: 19
Study 14641691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11053333 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA after exercise
Number of subjects: 8
Study 11053333 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA after sham
Number of subjects: 8
Study 9209787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (400 mg daily)
Number of subjects: 443
Study 9209787 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (AMX/CA, 500 mg/125 mg three times daily)
Number of subjects: 443
Study 9209787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (once-daily)
Number of subjects: 443
Study 9209787 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (twice-daily)
Number of subjects: 443
Study 7963779 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.150 mg i.v.
Number of subjects: 60